Intellia Therapeutics, INC. (NTLA) — 8-K Filings

8-K Filings (22)

• 8-K Filing — Nov 10, 2025
• Intellia Therapeutics Files 8-K — Oct 29, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting an event under "Other Events." The filing does not contain specific details about the ev
• Intellia Therapeutics Files 8-K — Oct 27, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure,
• Intellia Therapeutics Files 8-K — Sep 25, 2025 Risk: low
  On September 25, 2025, Intellia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial sta
• Intellia Therapeutics Files 8-K — Jun 16, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting events as of June 15, 2025. The filing primarily concerns Regulation FD disclosures, other
• Intellia Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes — Jun 12, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting events that occurred on June 11, 2025. The filing includes information regarding the depart
• Intellia Therapeutics Files 8-K — May 28, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on May 28, 2025, to report on events that occurred on the same date. The filing indicates it is for a Regulation FD Dis
• Intellia Therapeutics Files 8-K — May 19, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting events as of May 18, 2025. The filing includes information related to Regulation FD Disclosu
• Intellia Therapeutics Files 8-K with Bylaw Amendments — Apr 7, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting an event on April 3, 2025. The filing indicates amendments to its articles of incorporation
• Intellia Therapeutics Enters Material Definitive Agreement — Feb 21, 2025 Risk: medium
  Intellia Therapeutics, Inc. entered into a material definitive agreement on February 18, 2025. This agreement creates a direct financial obligation or an obliga
• Intellia Therapeutics Files 8-K — Jan 10, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting on events as of January 9, 2025. The filing covers results of operations, costs associat
• Intellia Therapeutics Files 8-K — Nov 18, 2024 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on events that occurred on November 16, 2024. The filing is categorized under Regulatio
• Intellia Therapeutics Files 8-K for Financials — Nov 7, 2024 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial state
• Intellia Therapeutics Partners with Regeneron for Autoimmune Disease Therapy — Oct 25, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on October 24, 2024, that it has entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceu
• Intellia Therapeutics Announces Executive Appointments — Jun 26, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on June 21, 2024, changes in its board of directors and executive compensation. Specifically, Dr. John Leonard has been ap
• Intellia Therapeutics Appoints New Officers, Adjusts Compensation — Jun 14, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on June 12, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Laura Hansen was appoint
• Intellia Therapeutics Files 8-K — Jun 13, 2024 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing det
• Intellia Therapeutics Announces Executive and Board Changes — Apr 15, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on April 10, 2024, changes in its executive and board leadership. Dr. John Leonard has been appointed as the new Chief Exe
• Intellia Therapeutics Terminates Deal with Regeneron — Mar 22, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on March 19, 2024, the termination of its material definitive agreement with Regeneron Pharmaceuticals, Inc. This terminat
• Intellia Therapeutics Enters Material Definitive Agreement — Feb 23, 2024 Risk: medium
  Intellia Therapeutics, Inc. filed an 8-K on February 23, 2024, to report the entry into a material definitive agreement. The filing indicates that the earliest
• Intellia Therapeutics Files Routine 8-K on Jan 31 Event — Feb 1, 2024
  Intellia Therapeutics, Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 31, 2024. This filing is a routine disclosure, specifi
• Intellia Therapeutics Files 8-K on Financial Condition, Other Events — Jan 4, 2024
  Intellia Therapeutics, Inc. filed an 8-K on January 4, 2024, to report on its 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and '

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX